ア・リズマブ

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/01/22 20:23:08」(JST)

Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.^[1]^[2]

References[edit]

^ Bayes M, Rabasseda X, Prous J (2003). "Gateways to clinical trials.". Methods Find Exp Clin Pharmacol 25 (9): 747–71. PMID 14685303.
^ Rech, J; Repp, R; Rech, D; Stockmeyer, B; Dechant, M; Niedobitek, G; Gramatzki, M; Valerius, T (2006). "A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study.". Leukemia & lymphoma 47 (10): 2147–54. doi:10.1080/10428190600757944. PMID 17071489.

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Arsenic trioxide and ascorbic acid demonstrate promising activity against primary human CLL cells in vitro.

Biswas S, Zhao X, Mone AP, Mo X, Vargo M, Jarjoura D, Byrd JC, Muthusamy N.SourceDivision of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Leukemia research.Leuk Res.2010 Jul;34(7):925-31. Epub 2010 Feb 19.
The compromised antioxidant defense system in chronic lymphocytic leukemia (CLL) suggested a potential use for reactive oxygen species (ROS) generating arsenic trioxide (ATO) and ascorbic acid. While both ATO and ascorbic acid mediate cytotoxicity in CLL B cells as single agents, the efficacy of ATO
PMID 20171736

Tay K, Dunleavy K, Wilson WH.SourceMetabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Leukemia & lymphoma.Leuk Lymphoma.2009 Dec;50(12):1911-3.
PMID 19886843

Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)

リンク元

「mab」